Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model

International Journal of Pharmaceutics

Volumn 384, Issue 1-2, 2010, Pages 46-52

  Watts, Alan B ^a   Cline, Adam M ^b   Saad, Adham R ^b   Johnson, Scott B ^b   Peters, Jay I ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Lung transplant; Nanoparticles; Preclinical; Pulmonary delivery; Tacrolimus

Indexed keywords

LUNG SURFACTANT; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RETENTION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; LIPOPHILICITY; LUNG TRANSPLANTATION; MALE; MEDICAL NEBULIZER; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; GRAFT REJECTION; LUNG; LUNG TRANSPLANTATION; MALE; MODELS, ANIMAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RATS; RATS, INBRED LEW; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 70649091111     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.09.040     Document Type: Article

References (28)

1. Akashi T., Nefuji T., Yoshida M., and Hosoda J. Quantitative determination of tautomeric fk506 by reversed-phase liquid chromatography. J. Pharm. Biomed. Anal. 14 (1996) 339-346
2. Arima H., Yunomae K., Hirayama F., and Uekama K. Contribution of p-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 297 (2001) 547-555
3. Astellas Pharmaceuticals, I, 2009. Prograf package insert. Astellas Pharma US, Inc.
4. Berg E., Svensson J.O., and Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J. Aerosol Med. 20 (2007) 97-104
5. Burckart G.J., Smaldone G.C., Eldon M.A., Venkataramanan R., Dauber J., Zeevi A., McCurry K.R., McKaveney T., Corcoran T.E., Griffith B.P., and Iacono A.T. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm. Res. 20 (2003) 252-256
6. Christie J.D., Edwards L.B., Aurora P., Dobbels F., Kirk R., Rahmel A.O., Taylor D.O., Kucheryavaya A.Y., and Hertz M.I. Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J. Heart Lung Transpl. 27 (2008) 957-969
7. Garrity E.R., and Mehra M.R. An update on clinical outcomes in heart and lung transplantation. Transplantation 77 (2004) S68-S74
8. Ghazanfari T., Elhissi A.M.A., Ding Z., and Taylor K.M.G. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int. J. Pharm. 339 (2007) 103-111
9. Hardaker L. Is evaporation the only process that affects aerosol particle size characterization with a next generation impactor in ambient and cooled states. Respiratory Drug Deliv. (2008) Scottsdale, Arizona
10. Ide N., Nagayasu T., Matsumoto K., Tagawa T., Tanaka K., Taguchi T., Sumida Y., and Nakashima M. Efficacy and saftey of inhaled tacrolimus in rat lung transplantation. J. Thorac. Cardiovasc. Surg. 133 (2007) 548-553
11. Ingu A., Komastu K., Ichimiya S., Sato N., Hirayama Y., Morikawa M., and Tomio A. Effects of inhaled fk 506 on the suppression of acute rejection after lung transplantation: Use of a rat orthotopic lung transplantation model. J. Heart Lung Transpl. 24 (2005) 538-543
12. Keenan R.J., Konishi H., Kawai A., Paradis I.L., Nunley D.R., Iacono A.T., Hardesty R.L., Weyant R.J., and Griffith B.P. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann. Thorac. Surg. 60 (1995) 580-584
13. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., and Aoki H. Fk-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of fk-506 in vitro. J. Antibiot. (Tokyo) 40 (1987) 1256-1265
14. Lamprecht A., Yamamoto H., Takeuchi H., and Kawashima Y. A pH-sensitive microsphere for the colon delivery of tacrolimus containing nanoparticles. J. Controlled Release 104 (2005) 337-346
15. McAllister S.M., Alpar H.O., Teitelbaum Z., and Bennett D.B. Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung?. Adv. Drug Del. Rev. 19 (1996) 89-110
16. Mizuta T., Kawaguchi A., Nakahara K., and Kawashima Y. Simplified rat lung transplantation using a cuff technique. J. Thorac. Cardiovasc. Surg. (1989) 97
17. O'Grady J.G., Burroughs A., Hardy P., Elboume D., and Truesdale A. Tacrolimus versus microemulsified ciclosproin in liver transplantation: the tmc randomised controlled trial. Lancet 360 (2002) 1119-1125
18. Overhoff K.A., Engstrom J.D., Chen B., Scherzer B.D., Milner T.E., Johnston K.P., and Williams III R.O. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 65 (2007) 57-67
19. Schrepfer S., Deuse T., Reichenspurner H., Hoffmann J., Haddad M., Fink J., Fischbein M.P., Robbins R.C., and Pelletier M.P. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. Am. J. Transpl. 7 (2007) 1733-1742
20. Sinswat P., Overhoff K.A., McConville J.T., Johnston K.P., and Williams III R.O. Nebulization of nanoparticulate amorphous or crystalline tacrolimus-single-dose pharmacokinetics study in mice. Eur. J. Pharm. Biopharm. 69 (2008) 1057-1066
21. Sweeney T.D., and Brain J.D. Pulmonary deposition: determinants and measurement techniques. Toxicol. Pathol. 19 (1991) 384-397
22. Tátrai E., Brozik M., Adamis Z., Merétey K., and Ungváry G. In vivo pulmonary toxicity of cellulose in rats. J. Appl. Toxicol. 16 (1996) 129-135
23. Trulock E.P., Christie J.D., Edwards L.B., Boucek M.M., Aurora P., Taylor D.O., Dobbels F., Rahmel A.O., Keck B.M., and Hertz M.I. Registry of the international society for heart and lung transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J. Heart Lung Transpl. 26 (2007) 782-795
24. Valberg P.A., Brain J.D., Sneddon S.A., and LeMott S.R. Breathing patterns influence aerosol deposition sites in excised dog lungs. J. Appl. Physiol. 53 (1982) 824-837
25. Verleden G.M., Dupont L.J., Van Raemdonck D., and Vanhaecke J. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J. Heart Lung Transpl. 22 (2003) 908-913
26. Watts A.B., Williams III R.O., and Peters J.I. Recent developments in drug delivery to prolong allograft survival in lung transplant patients. Drug Dev. Ind. Pharm. 35 (2009) 259-271
27. Welin-Berger K., and Bergenståhl B. Inhibition of ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. Int. J. Pharm. 200 (2000) 249-260
28. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., and Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 267 (2003) 79-91